Table 1

Baseline characteristics by eGFR categories <30, 30 to <45, 45 to <60, and ≥60 mL/min/1.73 m2

eGFR <30eGFR 30–<45eGFR 45–<60eGFR ≥60Overall
N (%)1,062 (15.2)1,938 (27.8)1,348 (19.3)2,631 (37.7)6,979 (100)
Age, years66.7 (9.5)68.8 (8.6)66.9 (8.6)62.8 (8.6)65.9 (9.1)
Male568 (53.5)1,121 (57.8)885 (65.7)1,816 (69.0)4,390 (62.9)
Region
 Europe (including South Africa)345 (32.5)788 (40.7)552 (40.9)1,249 (47.5)2,934 (42.0)
 Latin America409 (38.5)563 (29.1)426 (31.6)912 (34.7)2,310 (33.1)
 North America210 (19.8)419 (21.6)268 (19.9)283 (10.8)1,180 (16.9)
 Asia98 (9.2)168 (8.7)102 (7.6)187 (7.1)555 (8.0)
eGFR (MDRD), mL/min/1.73 m223.4 (4.2)37.2 (4.1)51.4 (4.4)81.6 (16.7)54.6 (25.0)
 <301,062 (100)0001,062 (15.2)
 <1521 (2.0)00021 (0.3)
UACR, mg/g, median (25th–75th percentile)585 (77–2,039)125 (24–719)223 (60–731)126 (46–412)162 (44–728)
UACR (mg/g)*
 <30159 (15.0)535 (27.6)214 (15.9)484 (18.4)1,392 (19.9)
 30–300293 (27.6)688 (35.5)566 (42.0)1,347 (51.2)2,894 (41.5)
 >300609 (57.3)714 (36.8)568 (42.1)799 (30.4)2,690 (38.5)
HbA1c, %7.9 (1.0)7.9 (1.0)8.0 (1.0)8.0 (1.0)8.0 (1.0)
HbA1c, mmol/mol62.5 (10.8)62.4 (10.7)63.7 (11.0)64.3 (11.2)63.4 (11.0)
Diabetes duration, years17.3 (9.8)16.6 (9.7)15.4 (9.5)12.0 (8.4)14.8 (9.5)
BMI, kg/m231.5 (5.6)31.6 (5.4)31.3 (5.3)30.9 (5.1)31.3 (5.3)
SBP/DBP, mmHg143 (20)/76 (11)141 (19)/76 (11)141 (18)/78 (10)139 (16)/79 (10)141 (18)/78 (10)
HF253 (23.8)512 (26.4)374 (27.7)734 (27.9)1,873 (26.8)
Insulin823 (77.5)1,288 (66.5)769 (57.0)1,171 (44.5)4,051 (58.0)
Metformin180 (16.9)717 (37.0)821 (60.9)2,090 (79.4)3,808 (54.6)
Sulfonylurea231 (21.8)543 (28.0)438 (32.5)1,030 (39.1)2,242 (32.1)
Any antihypertensives1,035 (97.5)1,877 (96.9)1,307 (97.0)2,472 (94.0)6,691 (95.9)
ACE inhibitors or ARBs797 (75.0)1,583 (81.7)1,145 (84.9)2,133 (81.1)5,658 (81.1)
Statins764 (71.9)1,432 (73.9)982 (72.8)1,840 (69.9)5,018 (71.9)
  • Data are n (%) or mean (SD) unless otherwise indicated.

  • ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure.

  • * Data missing for three (0.0%) participants: two (0.1%) linagliptin and one (0.0%) placebo.